[go: up one dir, main page]

WO1996037623B1 - Vecteurs retroviraux - Google Patents

Vecteurs retroviraux

Info

Publication number
WO1996037623B1
WO1996037623B1 PCT/GB1996/001230 GB9601230W WO9637623B1 WO 1996037623 B1 WO1996037623 B1 WO 1996037623B1 GB 9601230 W GB9601230 W GB 9601230W WO 9637623 B1 WO9637623 B1 WO 9637623B1
Authority
WO
WIPO (PCT)
Prior art keywords
retroviral vector
promoter
gene
retrovirus
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1996/001230
Other languages
English (en)
Other versions
WO1996037623A1 (fr
Filing date
Publication date
Priority claimed from GBGB9510272.9A external-priority patent/GB9510272D0/en
Application filed filed Critical
Priority to DK96914342T priority Critical patent/DK0827545T3/da
Priority to EP96914342A priority patent/EP0827545B1/fr
Priority to JP53549496A priority patent/JP3886531B2/ja
Priority to DE69619514T priority patent/DE69619514T2/de
Priority to US08/952,948 priority patent/US6096538A/en
Priority to AT96914342T priority patent/ATE213780T1/de
Publication of WO1996037623A1 publication Critical patent/WO1996037623A1/fr
Publication of WO1996037623B1 publication Critical patent/WO1996037623B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention porte sur des vecteurs rétroviraux qui sont utiles en thérapie génique. Un génome d'ARN encapsulable du vecteur constitue dans le provirus d'ADN un promoteur régulé qui est inductible par un facteur de régulation comme par exemple le transactivateur protéique Tat du VIH et par au moins un gène choisi dont la transcription est contrôlée par ce facteur. Dans le provirus d'ADN, le promoteur régulé est présent dans la répétition longue 5'-terminale à la place du promoteur de la répétition longue 5'-terminale du rétrovirus, et le gène choisi se trouve entre les répétitions longues terminales. Ainsi, lors de l'insertion dans la cellule hôte, le gène est exprimé uniquement quand le provirus d'ADN est exposé au facteur de régulation.
PCT/GB1996/001230 1995-05-22 1996-05-22 Vecteurs retroviraux Ceased WO1996037623A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK96914342T DK0827545T3 (da) 1995-05-22 1996-05-22 Retrovirale vektorer
EP96914342A EP0827545B1 (fr) 1995-05-22 1996-05-22 Vecteurs retroviraux
JP53549496A JP3886531B2 (ja) 1995-05-22 1996-05-22 レトロウイルスベクター
DE69619514T DE69619514T2 (de) 1995-05-22 1996-05-22 Retrovirale vektoren
US08/952,948 US6096538A (en) 1995-05-22 1996-05-22 Retroviral vectors
AT96914342T ATE213780T1 (de) 1995-05-22 1996-05-22 Retrovirale vektoren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9510272.9 1995-05-22
GBGB9510272.9A GB9510272D0 (en) 1995-05-22 1995-05-22 Retroviral vectors

Publications (2)

Publication Number Publication Date
WO1996037623A1 WO1996037623A1 (fr) 1996-11-28
WO1996037623B1 true WO1996037623B1 (fr) 1997-01-30

Family

ID=10774804

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001230 Ceased WO1996037623A1 (fr) 1995-05-22 1996-05-22 Vecteurs retroviraux

Country Status (10)

Country Link
US (1) US6096538A (fr)
EP (2) EP0827545B1 (fr)
JP (1) JP3886531B2 (fr)
AT (2) ATE340864T1 (fr)
DE (2) DE69619514T2 (fr)
DK (1) DK0827545T3 (fr)
ES (1) ES2170856T3 (fr)
GB (1) GB9510272D0 (fr)
PT (1) PT827545E (fr)
WO (1) WO1996037623A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688590B2 (en) 1994-09-02 1998-03-12 Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Non self-inactivating, expression targeted retroviral vectors
DK0817858T3 (da) 1995-03-09 2003-08-11 Gsf Forschungszentrum Umwelt Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
CA2244663A1 (fr) * 1996-02-13 1997-08-21 Fred Hutchinson Cancer Research Center Cellules d'encapsidation de vecteurs retroviraux 10a1 et utilisations de ce type de cellules
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
GB9703802D0 (en) 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
GB9711578D0 (en) * 1997-06-04 1997-07-30 Oxford Biomedica Ltd Novel retroviral vector production systems
EP1017797B1 (fr) 1997-09-24 2005-06-22 The Regents Of The University Of California Vecteurs de lentivirus non originaires de primates et systemes d'encapsidation
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
WO2001036614A2 (fr) 1999-11-16 2001-05-25 Geneart Gmbh Gessellschaft Für Angewandte Biotechnologie Genome de l'inter-sous-type vih-1 (c/b') et ses applications
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20030039636A1 (en) * 2001-05-01 2003-02-27 Genetix Pharmaceuticals, Inc. Novel self-inactivating (SIN) lentiviral vectors
CA2456169C (fr) 2001-08-02 2012-05-22 Didier Trono Procedes et compositions relatifs a des systemes production ameliores de vecteurs lentiviraux
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7919309B2 (en) * 2001-09-13 2011-04-05 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US7195916B2 (en) * 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
CA2462628C (fr) * 2001-10-02 2019-08-20 Institut Clayton De La Recherche Vecteurs lentiviraux a expression reduite
US9738907B2 (en) 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
EP2348119B1 (fr) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Vecteur de lentivirus multicistronique
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
WO2004048583A2 (fr) * 2002-11-22 2004-06-10 Institut Clayton De La Recherche Compositions et systemes destines a la regulation genique
US7297536B2 (en) * 2003-01-23 2007-11-20 Wisconsin Alumni Research Foundation Inducible protein expression system
ES2221578B1 (es) * 2003-06-13 2006-03-01 Universidad De Jaen Vector diseñado para la destruccion de los virus latentes en el tratamiento de la infeccion por el virus de la inmunodeficiencia humana tipo 1 (vih-1) mediante terapia genica.
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
JP7097465B2 (ja) 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
US20230002777A1 (en) 2019-11-12 2023-01-05 Oxford Biomedica (Uk) Limited Production System

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5672510A (en) * 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
EP1262554A3 (fr) * 1992-02-28 2007-08-29 Syngenix Limited Vecteurs non oncoviraux a encapsidation defectueuse bases sur le virus simiesque de mason-pfizer und hiv
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
WO1994029437A1 (fr) * 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Vecteurs retroviraux exempts de region u3, exempts de recombinaison, a auto-inactivation, hautement efficaces
EP0759471A4 (fr) * 1994-05-10 1997-10-15 Hisamitsu Pharmaceutical Co Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats

Similar Documents

Publication Publication Date Title
WO1996037623B1 (fr) Vecteurs retroviraux
GB9510272D0 (en) Retroviral vectors
Zaiss et al. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy
AU4712397A (en) Lentiviral vectors
Kim et al. Construction of retroviral vectors with improved safety, gene expression, and versatility
WO1995007995A3 (fr) Liposomes viraux adeno-associes et methodes associees
Knight et al. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing
CA2064092A1 (fr) Systeme efficace de clonage genetique directionnel
EP0914457A1 (fr) Procedes et compositions permettant de transformer des cellules
ATE291632T1 (de) Auf lentivirus basierende gentransfer-vektoren
CA1341119C (fr) Stimulateur de transcription specifique aux erythrocyles chez l'homme
CN1981047A (zh) Dna克隆载体质粒的动态载体装配方法
US5556954A (en) Hematopoietic stem cell specific gene expression
CA2435956A1 (fr) Methode de selection de clones de recombinaison comprenant une sequence codant une proteine antidote destinee a une molecule toxique
EP0953647A4 (fr) Procede pour preparer un vecteur de retrovirus pour la therapie genique
US6534314B1 (en) Methods and compositions for transforming cells
US20020042136A1 (en) Retroviral vectors comprising an enhanced 3' transcription termination structure
GB2331989B (en) Retroviral vectors
RU99109988A (ru) Лентивирусные векторы
Kim et al. Tetracycline-mediated suppression of gene expression with a new dicistronic retroviral vector
HK1020752B (en) Methods and compositions for transforming cells